

PATIENT INTEREST IN USING NEW DEPOT FORMULATION OF BUPRENORPHINE IN PENITENTIARY CARE CENTERS IN FRANCE – RESULTS FROM THE AMBRE SURVEY

Authors: [Fadi Meroueh](#)¹, Aurelie Mieuset¹, Peter Hjelmström², Margaux Kosim^{3,4}

¹Unité Sanitaire, CHU de Montpellier, France

² Camurus AB, Ideon Science Park, Lund, Sweden

³ Consultations de médecine-Addictologie PASS, Groupe Hospitalier Pitié Salpêtrière, 47/83 boulevard de l'Hôpital, 75013 Paris, France

⁴ Camurus SAS, Paris, France

Presenter's email: fadimeroueh@gmail.com

Introduction and Aims: The perception of Opioid pharmacotherapy (OT) is known to be different according to opioid user's profile. As such, patient's preference is an important criterion for the choice of OT by healthcare professionals.

In France, a survey (AMBRE) was conducted to understand patients' willingness to use a new long-acting formulation of buprenorphine available as an injectable treatment by subcutaneous administration in weekly and monthly formulations. There has been a particular interest in the depot formulations in the criminal justice settings and this study will focus on perceptions of patients in prisons.

Design and Methods: The AMBRE study was conducted among opioid dependent patients in France by general-practitioners or specialists in CSAPA (Centers of Addiction) or USMP (Consultation in prison), from February to May 2019. Patients enrolled were ≥18 years, currently treated or initiating OT, accepting to participate and able to complete self-questionnaires with two parts.

This abstract will report the data for USMP-patients in penitentiary settings

Results: The first preliminary results indicate a total of 3 centers included 43 USMP-patients among 180 patients globally. All USMP-patients were male and 41.9% were [45-54] years. Median duration of OT was 20 years. For 83.7% of patients (n=36), OT is perceived as a mean to decrease or stop definitely opioid use. 67.4% of patients (n=29), find it however embarrassing to go often to pharmacy/center to collect their OT. Most important reported objective regarding depot formulations was to stop thinking daily about it (81.4%, n=35). Finally, 62.8% (n=27) of USMP-patients declared being interested to change their current OT for this new formulation.

Discussions and Conclusions: USMP-patients seem to be interested in the new buprenorphine formulation. Final analysis, that will be performed on 100 USMP-patients, will consolidate this data.

Disclosure of Interest Statement: Nil